Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Enamel matrix proteins (EMPs) represent a diverse group of secreted, primarily tooth-specific proteins including **amelogenin**, **enamelin**, **ameloblastin** (also known as amelin or sheathlin), **tuftelin**, and **amelotin**[2][4][8]. These proteins are mainly produced by ameloblasts during enamel formation and collectively make up the organic matrix of developing enamel, where they regulate the nucleation, growth, and organization of hydroxyapatite crystals, resulting in the highly mineralized structure of tooth enamel[2][6][8]. Amelogenin constitutes the majority (about 90%+) of the EMPs and is key for the development and architecture of enamel[3][5][6]. Additional roles for EMPs include initiation of cementum (root covering) deposition, periodontal attachment formation (through derivatives such as EMD), and possibly non-canonical biological effects outside dental tissues (e.g., growth factor-like activity, signaling, calcium metabolism)[3][4][8]. Mutations in genes coding for EMPs are linked to dental disorders such as amelogenesis imperfecta[1]. EMP derivatives, particularly EMD (Emdogain), are used in regenerative periodontal therapy[7]. EMPs are not a single druggable molecular target, receptor, or enzyme but rather a protein family or mixture, and thus should not be listed as a conventional therapeutic target; instead, specific members (e.g., amelogenin, enamelin) may have more structured target entries. The term "enamel matrix proteins" is generic, referring collectively to several related and functionally interconnected proteins, and does not describe a single molecular target suitable for most drug discovery or receptor-oriented frameworks. For structured applications, each major component (e.g., "Amelogenin", "Enamelin") should be treated as distinct entries. EMPs themselves act as structural and functional mediators but are not classic receptors, enzymes, or transporters. Their use in therapy is through protein extracts (EMD), not small-molecule modulation of a defined target[3][7].
Biomimetic stimulation of tissue regeneration; modulation of cellular differentiation and proliferation; enhancement of periodontal ligament and bone regeneration
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Enamel matrix protein (EMP).